Global Identification of Protein Prenyltransferase Substrates. Defining the Prenylated Proteome.

Enzymes

Volumn 29, Issue , 2011, Pages 207-234

  Lamphear, Corissa L ^a   Zverina, Elaina A ^b   Hougland, James L ^b   Fierke, Carol A ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Farnesylation; Geranylgeranylation; Prenylation; Protein farnesyltransferase; Protein geranylgeranyltransferase; Substrate specificity

Indexed keywords

EID: 79960282811     PISSN: 18746047     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-381339-8.00012-3     Document Type: Chapter

References (107)

1. Zhang F.L., Casey P.J. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996, 65:241-269.
2. Benetka W., Koranda M., Eisenhaber F. Protein prenylation: an (almost) comprehensive overview on discovery history, enzymology, and significance in physiology and disease. Monatsh Chem Chem Mon 2006, 137:1241-1281.
3. Marshall C.J. Protein prenylation: a mediator of protein-protein interactions. Science 1993, 259:1865-1866.
4. Casey P.J. Lipid modifications of G proteins. Curr Opin Cell Biol 1994, 6:219-225.
5. Casey P.J., Seabra M.C. Protein prenyltransferases. J Biol Chem 1996, 271:5289-5292.
6. Winter-Vann A.M., Casey P.J. Post-prenylation-processing enzymes as new targets in oncogenesis. Nat Rev Cancer 2005, 5:405-412.
7. Barrowman J., Michaelis S. ZMPSTE24, an integral membrane zinc metalloprotease with a connection to progeroid disorders. Biol Chem 2009, 390:761-773.
8. Trueblood C.E., Boyartchuk V.L., Picologlou E.A., Rozema D., Poulter C.D., Rine J. The CaaX proteases, Afc1p and Rce1p, have overlapping but distinct substrate specificities. Mol Cell Biol 2000, 20:4381-4392.
9. Seabra M.C., Reiss Y., Casey P.J., Brown M.S., Goldstein J.L. Protein farnesyltransferase and geranylgeranyltransferase share a common alpha subunit. Cell 1991, 65:429-434.
10. Lane K.T., Beese L.S. Thematic review series: lipid posttranslational modifications. Structural biology of protein farnesyltransferase and geranylgeranyltransferase type I. J Lipid Res 2006, 47:681-699.
11. Kho Y., et al. A tagging-via-substrate technology for detection and proteomics of farnesylated proteins. Proc Natl Acad Sci USA 2004, 101:12479-12484.
12. Maurer-Stroh S., Eisenhaber F. Refinement and prediction of protein prenylation motifs. Genome Biol 2005, 6:R55.
13. Maurer-Stroh S., Koranda M., Benetka W., Schneider G., Sirota F.L., Eisenhaber F. Towards complete sets of farnesylated and geranylgeranylated proteins. PLoS Comput Biol 2007, 3:e66.
14. Reid T.S., Terry K.L., Casey P.J., Beese L.S. Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity. J Mol Biol 2004, 343:417-433.
15. Hougland J.L., Hicks K.A., Hartman H.L., Kelly R.A., Watt T.J., Fierke C.A. Identification of novel peptide substrates for protein farnesyltransferase reveals two substrate classes with distinct sequence selectivities. J Mol Biol 2010, 395:176-190.
16. Samuel F., Hynds D.L. RHO GTPase signaling for axon extension: is prenylation important?. Mol Neurobiol 2010, 42:133-142.
17. Rusinol A.E., Sinensky M.S. Farnesylated lamins, progeroid syndromes and farnesyl transferase inhibitors. J Cell Sci 2006, 119:3265-3272.
18. Basso A.D., Kirschmeier P., Bishop W.R. Lipid posttranslational modifications. Farnesyl transferase inhibitors. J Lipid Res 2006, 47:15-31.
19. Sousa S.F., Fernandes P.A., Ramos M.J. Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem. Curr Med Chem 2008, 15:1478-1492.
20. Young S.G., Meta M., Yang S.H., Fong L.G. Prelamin A farnesylation and progeroid syndromes. J Biol Chem 2006, 281:39741-39745.
21. Nallan L., et al. Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J Med Chem 2005, 48:3704-3713.
22. Sepp-Lorenzino L., et al. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 1995, 55:5302-5309.
23. Nonaka M., et al. Role for protein geranylgeranylation in adult T-cell leukemia cell survival. Exp Cell Res 2009, 315:141-150.
24. Chiba Y., Sato S., Hanazaki M., Sakai H., Misawa M. Inhibition of geranylgeranyltransferase inhibits bronchial smooth muscle hyperresponsiveness in mice. Am J Physiol Lung Cell Mol Physiol 2009, 297:L984-L991.
25. Ridker P.M., et al. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med 2008, 359(21):2195-2207.
26. Casey P.J. Protein lipidation in cell signaling. Science 1995, 268:221-225.
27. Caplin B.E., Hettich L.A., Marshall M.S. Substrate characterization of the Saccharomyces cerevisiae protein farnesyltransferase and type-I protein geranylgeranyltransferase. Biochim Biophys Acta 1994, 1205:39-48.
28. Omer C.A., et al. Characterization of recombinant human farnesyl-protein transferase: cloning, expression, farnesyl diphosphate binding, and functional homology with yeast prenyl-protein transferases. Biochemistry 1993, 32:5167-5176.
29. Reiss Y., Stradley S.J., Gierasch L.M., Brown M.S., Goldstein J.L. Sequence requirement for peptide recognition by rat brain p21ras protein farnesyltransferase. Proc Natl Acad Sci USA 1991, 88:732-736.
30. Moores S.L., et al. Sequence dependence of protein isoprenylation. J Biol Chem 1991, 266:14603-14610.
31. Hicks K.A., Hartman H.L., Fierke C.A. Upstream polybasic region in peptides enhances dual specificity for prenylation by both farnesyltransferase and geranylgeranyltransferase type I. Biochemistry 2005, 44:15325-15333.
32. Gelb M.H., et al. Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. Mol Biochem Parasitol 2003, 126:155-163.
33. Bulbule V.J., Rivas K., Verlinde C.L., Van Voorhis W.C., Gelb M.H. 2-Oxotetrahydroquinoline-based antimalarials with high potency and metabolic stability. J Med Chem 2008, 51:384-387.
34. Fletcher S., et al. Potent, plasmodium-selective farnesyltransferase inhibitors that arrest the growth of malaria parasites: structure-activity relationships of ethylenediamine-analogue scaffolds and homology model validation. J Med Chem 2008, 51:5176-5197.
35. Smalera I., Williamson J.M., Baginsky W., Leiting B., Mazur P. Expression and characterization of protein geranylgeranyltransferase type I from the pathogenic yeast Candida albicans and identification of yeast selective enzyme inhibitors. Biochim Biophys Acta 2000, 1480:132-144.
36. Song J.L., White T.C. RAM2: an essential gene in the prenylation pathway of Candida albicans. Microbiology 2003, 149:249-259.
37. Mazur P., et al. Purification of geranylgeranyltransferase I from Candida albicans and cloning of the CaRAM2 and CaCDC43 genes encoding its subunits. Microbiology 1999, 145(Pt 5):1123-1135.
38. Kelly R., et al. Geranylgeranyltransferase I of Candida albicans: null mutants or enzyme inhibitors produce unexpected phenotypes. J Bacteriol 2000, 182:704-713.
39. Eastman R.T., Buckner F.S., Yokoyama K., Gelb M.H., Van Voorhis W.C. Thematic review series: lipid posttranslational modifications. Fighting parasitic disease by blocking protein farnesylation. J Lipid Res 2006, 47:233-240.
40. Eastman R.T., et al. Resistance mutations at the lipid substrate binding site of Plasmodium falciparum protein farnesyltransferase. Mol Biochem Parasitol 2007, 152:66-71.
41. Ivanov S.S., Charron G., Hang H.C., Roy C.R. Lipidation by the host prenyltransferase machinery facilitates membrane localization of Legionella pneumophila effector proteins. J Biol Chem 2010, 285:34686-34698.
42. Price C.T., Al-Quadan T., Santic M., Jones S.C., Abu Kwaik Y. Exploitation of conserved eukaryotic host cell farnesylation machinery by an F-box effector of Legionella pneumophila. J Exp Med 2010, 207:1713-1726.
43. Hancock J.F. Reticulocyte lysate assay for in vitro translation and posttranslational modification of Ras proteins. Methods Enzymol 1995, 255:60-65.
44. Wilson A.L., Maltese W.A. Coupled Translation/Prenylation of Rab Proteins in-Vitro. Lipid Modifications of Proteins 1995, Academic Press Inc., San Diego, Vol. 250, pp. 79-91.
45. Gibbs B.S., Zahn T.J., Mu Y., Sebolt-Leopold J.S., Gibbs R.A. Novel farnesol and geranylgeraniol analogues: a potential new class of anticancer agents directed against protein prenylation. J Med Chem 1999, 42:3800-3808.
46. Peter M., Chavrier P., Nigg E.A., Zerial M. Isoprenylation of Rab proteins on structurally distinct cysteine motifs. J Cell Sci 1992, 102:857-865.
47. Corsini A., Farnsworth C.C., McGeady P., Gelb M.H., Glomset J.A. Incorporation of radiolabeled prenyl alcohols and their analogs into mammalian cell proteins. A useful tool for studying protein prenylation. Methods Mol Biol 1999, 116:125-144.
48. Andres D.A., Crick D.C., Finlin B.S., Waechter C.J. Rapid identification of cysteine-linked isoprenyl groups by metabolic labeling with [3H]farnesol and [3H]geranylgeraniol. Methods Mol Biol 1999, 116:107-123.
49. Benetka W., Koranda M., Maurer-Stroh S., Pittner F., Eisenhaber F. Farnesylation or geranylgeranylation? Efficient assays for testing protein prenylation in vitro and in vivo. BMC Biochem 2006, 7:6.
50. Liu Z.H., et al. Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease. Proc Natl Acad Sci USA 2009, 106:4635-4640.
51. Baron R., et al. RhoB prenylation is driven by the three carboxyl-terminal amino acids of the protein: evidenced in vivo by an anti-farnesyl cysteine antibody. Proc Natl Acad Sci USA 2000, 97:11626-11631.
52. Lin H.P., Hsu S.C., Wu J.C., Sheen I.J., Yan B.S., Syu W.J. Localization of isoprenylated antigen of hepatitis delta virus by anti-farnesyl antibodies. J Gen Virol 1999, 80(Pt 1):91-96.
53. Liu X.H., Suh D.Y., Call J., Prestwich G.D. Antigenic prenylated peptide conjugates and polyclonal antibodies to detect protein prenylation. Bioconjug Chem 2004, 15:270-277.
54. Troutman J.M., Roberts M.J., Andres D.A., Spielmann H.P. Tools to analyze protein farnesylation in cells. Bioconjug Chem 2005, 16:1209-1217.
55. Nguyen U.T., et al. Analysis of the eukaryotic prenylome by isoprenoid affinity tagging. Nat Chem Biol 2009, 5:227-235.
56. Nguyen U.T.T., Goody R.S., Alexandrov K. Understanding and exploiting protein prenyltransferases. Chembiochem 2010, 11:1194-1201.
57. Chehade K.A., Andres D.A., Morimoto H., Spielmann H.P. Design and synthesis of a transferable farnesyl pyrophosphate analogue to Ras by protein farnesyltransferase. J Org Chem 2000, 65:3027-3033.
58. Onono F.O., et al. A tagging-via-substrate approach to detect the farnesylated proteome using two-dimensional electrophoresis coupled with Western blotting. Mol Cell Proteomics 2010, 9:742-751.
59. Saxon E., Bertozzi C.R. Cell surface engineering by a modified Staudinger reaction. Science 2000, 287:2007-2010.
60. Moses J.E., Moorhouse A.D. The growing applications of click chemistry. Chem Soc Rev 2007, 36:1249-1262.
61. Chan L.N., et al. A novel approach to tag and identify geranylgeranylated proteins. Electrophoresis 2009, 30:3598-3606.
62. Berry A.F., et al. Rapid multilabel detection of geranylgeranylated proteins by using bioorthogonal ligation chemistry. Chembiochem 2010, 11:771-773.
63. Charron G., Tsou L.K., Maguire W., Yount J.S., Hang H.C. Alkynyl-farnesol reporters for detection of protein S-prenylation in cells. Mol Biosyst 2011, 7:67-73.
64. DeGraw A.J., et al. Evaluation of alkyne-modified isoprenoids as chemical reporters of protein prenylation. Chem Biol Drug Des 2010, 76:460-471.
65. Labadie G.R., Viswanathan R., Poulter C.D. Farnesyl diphosphate analogues with omega-bioorthogonal azide and alkyne functional groups for protein farnesyl transferase-catalyzed ligation reactions. J Org Chem 2007, 72:9291-9297.
66. Reigard S.A., Zahn T.J., Haworth K.B., Hicks K.A., Fierke C.A., Gibbs R.A. Interplay of isoprenoid and peptide substrate specificity in protein farnesyltransferase. Biochemistry 2005, 44:11214-11223.
67. Krzysiak A.J., et al. Combinatorial modulation of protein prenylation. ACS Chem Biol 2007, 2:385-389.
68. Troutman J.M., Subramanian T., Andres D.A., Spielmann H.P. Selective modification of CaaX peptides with ortho-substituted anilinogeranyl lipids by protein farnesyl transferase: competitive substrates and potent inhibitors from a library of farnesyl diphosphate analogues. Biochemistry 2007, 46:11310-11321.
69. Terry K.L., Casey P.J., Beese L.S. Conversion of protein farnesyltransferase to a geranylgeranyltransferase. Biochemistry 2006, 45:9746-9755.
70. Luckman S.P., Hughes D.E., Coxon F.P., Russell R.G.G., Rogers M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998, 13:581-589.
71. Taylor J.S., Reid T.S., Terry K.L., Casey P.J., Beese L.S. Structure of mammalian protein geranylgeranyltransferase type-I. EMBO J 2003, 22:5963-5974.
72. Long S.B., Casey P.J., Beese L.S. Reaction path of protein farnesyltransferase at atomic resolution. Nature 2002, 419:645-650.
73. Hartman H.L., Hicks K.A., Fierke C.A. Peptide specificity of protein prenyltransferases is determined mainly by reactivity rather than binding affinity. Biochemistry 2005, 44:15314-15324.
74. Krzysiak A.J., Aditya A.V., Hougland J.L., Fierke C.A., Gibbs R.A. Synthesis and screening of a CaaL peptide library versus FTase reveals a surprising number of substrates. Bioorg Med Chem Lett 2009, 20:767-770.
75. Hougland J.L., Lamphear C.L., Scott S.A., Gibbs R.A., Fierke C.A. Context-dependent substrate recognition by protein farnesyltransferase. Biochemistry 2009, 48:1691-1701.
76. Goldstein J.L., Brown M.S., Stradley S.J., Reiss Y., Gierasch L.M. Nonfarnesylated tetrapeptide inhibitors of protein farnesyltransferase. J Biol Chem 1991, 266:15575-15578.
77. Pompliano D.L., Gomez R.P., Anthony N.J. Intramolecular fluorescence enhancement-a continuous assay of ras farnesyl-protein transferase. J Am Chem Soc 1992, 114:7945-7946.
78. Hightower K.E., Huang C.C., Casey P.J., Fierke C.A. H-Ras peptide and protein substrates bind protein farnesyltransferase as an ionized thiolate. Biochemistry 1998, 37:15555-15562.
79. Cassidy P.B., Dolence J.M., Poulter C.D. Continuous fluorescence assay for protein prenyltransferases. Methods Enzymol 1995, 250:30-43.
80. Boutin J.A., et al. Investigation of S-farnesyl transferase substrate specificity with combinatorial tetrapeptide libraries. Cell Signal 1999, 11:59-69.
81. Krzysiak A.J., Scott S.A., Hicks K.A., Fierke C.A., Gibbs R.A. Evaluation of protein farnesyltransferase substrate specificity using synthetic peptide libraries. Bioorg Med Chem Lett 2007, 17:5548-5551.
82. Fersht A. Structure and Mechanism in Protein Science 1999, W.H. Freeman and Company, New York, NY.
83. Pompliano D.L., Schaber M.D., Mosser S.D., Omer C.A., Shafer J.A., Gibbs J.B. Isoprenoid diphosphate utilization by recombinant human farnesyl:protein transferase: interactive binding between substrates and a preferred kinetic pathway. Biochemistry 1993, 32:8341-8347.
84. Zimmerman K.K., Scholten J.D., Huang C.C., Fierke C.A., Hupe D.J. High-level expression of rat farnesyl:protein transferase in Escherichia coli as a translationally coupled heterodimer. Protein Expr Purif 1998, 14:395-402.
85. Pais J.E., Bowers K.E., Stoddard A.K., Fierke C.A. A continuous fluorescent assay for protein prenyltransferases measuring diphosphate release. Anal Biochem 2005, 345:302-311.
86. Furfine E.S., Leban J.J., Landavazo A., Moomaw J.F., Casey P.J. Protein farnesyltransferase: kinetics of farnesyl pyrophosphate binding and product release. Biochemistry 1995, 34:6857-6862.
87. Tschantz W.R., Furfine E.S., Casey P.J. Substrate binding is required for release of product from mammalian protein farnesyltransferase. J Biol Chem 1997, 272:9989-9993.
88. Bowers K.E., Fierke C.A. Positively charged side chains in protein farnesyltransferase enhance catalysis by stabilizing the formation of the diphosphate leaving group. Biochemistry 2004, 43:5256-5265.
89. Long S.B., Hancock P.J., Kral A.M., Hellinga H.W., Beese L.S. The crystal structure of human protein farnesyltransferase reveals the basis for inhibition by CaaX tetrapeptides and their mimetics. Proc Natl Acad Sci USA 2001, 98:12948-12953.
90. Pickett J.S., et al. Kinetic studies of protein farnesyltransferase mutants establish active substrate conformation. Biochemistry 2003, 42:9741-9748.
91. Pais J.E., Bowers K.E., Fierke C.A. Measurement of the alpha-secondary kinetic isotope effect for the reaction catalyzed by mammalian protein farnesyltransferase. J Am Chem Soc 2006, 128:15086-15087.
92. Troutman J.M., Andres D.A., Spielmann H.P. Protein farnesyl transferase target selectivity is dependent upon peptide stimulated product release. Biochemistry 2007, 46:11299-11309.
93. Spence R.A., Hightower K.E., Terry K.L., Beese L.S., Fierke C.A., Casey P.J. Conversion of Tyr361 beta to Leu in mammalian protein farnesyltransferase impairs product release but not substrate recognition. Biochemistry 2000, 39:13651-13659.
94. Falquet L., et al. The PROSITE database, its status in 2002. Nucleic Acids Res 2002, 30:235-238.
95. McGeady P., Logan D.A., Wansley D.L. A protein-farnesyl transferase inhibitor interferes with the serum-induced conversion of Candida albicans from a cellular yeast form to a filamentous form. FEMS Microbiol Lett 2002, 213:41-44.
96. Murthi K.K., Smith S.E., Kluge A.F., Bergnes G., Bureau P., Berlin V. Antifungal activity of a Candida albicans GGTase I inhibitor-alanine conjugate. Inhibition of Rho1p prenylation in C. albicans. Bioorg Med Chem Lett 2003, 13:1935-1937.
97. Nishimura S., et al. Massadine, a novel geranylgeranyltransferase type I inhibitor from the marine sponge Stylissa aff. massa. Org Lett 2003, 5:2255-2257.
98. Hast M.A., Beese L.S. Structure of protein geranylgeranyltransferase-I from the human pathogen Candida albicans complexed with a lipid substrate. J Biol Chem 2008, 283:31933-31940.
99. Trueblood C.E., Ohya Y., Rine J. Genetic evidence for in vivo cross-specificity of the CaaX-box protein prenyltransferases farnesyltransferase and geranylgeranyltransferase-I in Saccharomyces cerevisiae. Mol Cell Biol 1993, 13:4260-4275.
100. He B., Chen P., Chen S.Y., Vancura K.L., Michaelis S., Powers S. RAM2, an essential gene of yeast, and RAM1 encode the two polypeptide components of the farnesyltransferase that prenylates a-factor and Ras proteins. Proc Natl Acad Sci USA 1991, 88:11373-11377.
101. Ohya Y., Qadota H., Anraku Y., Pringle J.R., Botstein D. Suppression of yeast geranylgeranyl transferase I defect by alternative prenylation of two target GTPases, Rho1p and Cdc42p. Mol Biol Cell 1993, 4:1017-1025.
102. Zink S.D., Pedersen L., Cianciotto N.P., Abu-Kwaik Y. The Dot/Icm type IV secretion system of Legionella pneumophila is essential for the induction of apoptosis in human macrophages. Infect Immun 2002, 70:1657-1663.
103. Price C.T., Al-Khodor S., Al-Quadan T., Abu Kwaik Y. Indispensable role for the eukaryotic-like ankyrin domains of the ankyrin B effector of Legionella pneumophila within macrophages and amoebae. Infect Immun 2010, 78:2079-2088.
104. Price C.T., et al. Molecular mimicry by an F-box effector of Legionella pneumophila hijacks a conserved polyubiquitination machinery within macrophages and protozoa. PLoS Pathog 2009, 5:e1000704.
105. Al-Khodor S., Price C.T., Habyarimana F., Kalia A., Abu Kwaik Y. A Dot/Icm-translocated ankyrin protein of Legionella pneumophila is required for intracellular proliferation within human macrophages and protozoa. Mol Microbiol 2008, 70:908-923.
106. Long S.B., Casey P.J., Beese L.S. The basis for K-Ras4B binding specificity to protein farnesyltransferase revealed by 2 A resolution ternary complex structures. Structure 2000, 8:209-222.
107. Pompliano D.L., Rands E., Schaber M.D., Mosser S.D., Anthony N.J., Gibbs J.B. Steady-state kinetic mechanism of Ras farnesyl:protein transferase. Biochemistry 1992, 31:3800-3807.